SCHEMBL6204319

SCHEMBL6204319

CC1CCC(NC(=O)c2cccs2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.73
NPC1 O15118 4/20 0.73
ALDH1A1 P00352 4/20 0.72
HPGD P15428 3/20 0.72
TSHR P16473 2/20 0.72
MEN1 O00255 1/20 0.72
CYP1A2 P05177 1/20 0.72
CYP3A4 P08684 1/20 0.72
CYP2D6 P10635 1/20 0.72
CYP2C19 P33261 1/20 0.72
KMT2A Q03164 1/20 0.72
GAA P10253 2/20 0.61
GFER P55789 1/20 0.61
HSD17B10 Q99714 1/20 0.60
L3MBTL1 Q9Y468 2/20 0.58
ATM Q13315 1/20 0.58
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HDAC1 Q13547 1/20 0.51
DRD2 P14416 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204318 1.00 RAB9A (0.73) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL825926 0.92 RAB9A (0.84) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL12181432 0.85 RAB9A (0.90) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL3456092 0.84 RAB9A (1.00) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL12181229 0.84 RAB9A (1.00) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL359241 0.83 RAB9A (0.74) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL12858327 0.77 ALDH1A1 (0.55) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL27876089 0.77 RAB9A (0.66) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL14568945 0.75 TSHR (0.60) RAB9ANPC1ALDH1A1HPGDTSHR
SCHEMBL10827784 0.75 RAB9A (0.58) RAB9ANPC1ALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595871-A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases NPS PHARMACEUTICALS, INC. (US) 2005-11-16 EP disclosed